Jose, Jesna
,
Al-Dorzi, Hasan M. http://orcid.org/0000-0002-3772-8949
Al-Omari, Awad
Mandourah, Yasser
Al-Hameed, Fahad
Sadat, Musharaf
Al Qasim, Eman
Alraddadi, Basem
Al Harthy, Abdulrahman
Al Mekhlafi, Ghaleb A.
Almotairi, Abdullah
Al Khatib, Kasim
Abdulmomen, Ahmed
Qushmaq, Ismael
Sindi, Anees A.
Mady, Ahmed
Solaiman, Othman
Al-Raddadi, Rajaa
Maghrabi, Khalid
Ragab, Ahmed
Kharaba, Ayman
Shalhoub, Sarah
Al-Aithan, Abdulsalam M.
Vishwakarma, Gajendra K.
Bhattacharjee, Atanu
Arabi, Yaseen M. http://orcid.org/0000-0001-5735-6241
Article History
Received: 12 August 2020
Accepted: 6 January 2021
First Online: 19 January 2021
Consent for publication
: All the authors have read the final manuscript and approved its submission.
: Yaseen Arabi provided nonpaid consultations on therapeutics for MERS for Gilead Sciences and SAB Biotherapeutics and he is a Board Member of the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC). He is the Lead-Co Chair of the Think-20 Saudi Arabia (T20) Taskforce for COVID-19. Other authors declared that they have no competing interests.